Consumer Discretionary Company Tapestry Announces Acquisition of Capri Holdings

Tapestry (NYSE:TPR) has announced an acquisition of Capri Holdings (NYSE:CPRI) that is expected to be completed 2024. Under…

Tapestry (NYSE:TPR) has announced an acquisition of Capri Holdings (NYSE:CPRI) that is expected to be completed 2024.

Under the terms of the agreement, Tapestry has agreed to give Capri Holdings $8.50 billion in cash in exchange for CPRI stock.

About The Companies Involved

Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm’s products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere.

Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Michael Kors, Capri’s largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce.

How An Acquisition Works

An acquisition is when one company, called the acquiring company, buys most or all of another company’s, or target company’s, shares to gain ownership. Buying more than 50% of a company’s stock allows the the acquirer to make decisions without the approval of the company’s shareholders.

An acquisition can potentially lead to a merger with the parent company, which makes it similar to a merger. This is why the two terms are commonly grouped together as mergers and acquisitions (M&A). However, in a merger, the leadership & operations of both companies usually change dramatically, while during an acquisition this is less likely to happen.

Make sure to follow our mergers & acquisitions calendar to stay-up-to-date on the most recent M&A deals.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Takeda Announces Late-Breaking Data From Phase 2b Study Of TAK-279, An Investigational, Oral, Once-Daily TYK2 Inhibitor, In Patients With Active Psoriatic Arthritis At American College Of Rheumatology Convergence Annual Meeting

− The Study Met Its Primary Endpoint with 53.3% and 54.2% of Patients Treated With TAK-279 (15 mg and 30 mg Respectively) Achieving At Least an ACR 20 Response Compared to 29.2% in the Placebo Group at Week 12 (p =

TAK

Read More

Recap: Pentair Q2 Earnings

  Pentair (NYSE:PNR) reported its Q2 earnings results on Tuesday, July 26, 2022 at 06:55 AM. Here's what investors need to know about the announcement. Earnings Pentair beat estimated earnings by 2.0%, reporting an EPS of $1.02 versus an estimate of $1.0.

PNR